Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP496739.RAAuKISyBr0PgDrtR58AlSZYotmfGZy1MzBcE5ZZJfiaY130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496739.RAAuKISyBr0PgDrtR58AlSZYotmfGZy1MzBcE5ZZJfiaY130_provenance.
• NP496752.RAD0Idx2JSAbFhPRyWNeUfE9vTiCBcJjU5VF8m9foF_Kw130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496752.RAD0Idx2JSAbFhPRyWNeUfE9vTiCBcJjU5VF8m9foF_Kw130_provenance.
• NP496738.RAR42tg5vytI45f2JBLLoN3wdnBHHlwrw_1_0IEsKr4hc130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496738.RAR42tg5vytI45f2JBLLoN3wdnBHHlwrw_1_0IEsKr4hc130_provenance.
• NP496742.RASxHb8LemI9ZoPf-CzzHPAiVEZTn6PHatvP-nLPHKVjs130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496742.RASxHb8LemI9ZoPf-CzzHPAiVEZTn6PHatvP-nLPHKVjs130_provenance.
• NP496746.RAR5Qz3MrU314WeKmFDndJak0zXlM9hzrn_kS7oAhn61w130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496746.RAR5Qz3MrU314WeKmFDndJak0zXlM9hzrn_kS7oAhn61w130_provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP978541.RAuzAIO2dWSk2pIZJSXdn8CxybwUlxVWyGbKm5wHqc2Zs130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978541.RAuzAIO2dWSk2pIZJSXdn8CxybwUlxVWyGbKm5wHqc2Zs130_provenance.
• NP873206.RAh0f_SowivnxUg5eF4E-ziODkKqtkIQWRykJ2-3glY-k130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873206.RAh0f_SowivnxUg5eF4E-ziODkKqtkIQWRykJ2-3glY-k130_provenance.
• NP496749.RAsR5gnSdVXn3NXlUYKE0pjmKOIIEwYrz7vJ4u7lmZkT0130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496749.RAsR5gnSdVXn3NXlUYKE0pjmKOIIEwYrz7vJ4u7lmZkT0130_provenance.
• NP605854.RA3BkRqgYlFm6EL-v0PwEkz4BWfemxW-AEUxGDXt8Akgo130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605854.RA3BkRqgYlFm6EL-v0PwEkz4BWfemxW-AEUxGDXt8Akgo130_provenance.
• NP605999.RAwINUglHL6OVe-eQUqn4WiL8pgNC-NMUxknSnEo-QC_Y130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605999.RAwINUglHL6OVe-eQUqn4WiL8pgNC-NMUxknSnEo-QC_Y130_provenance.
• NP781302.RAHcpyCqVX-A5GpDeV7l-YPb-CO6m8670lzuO0v9J9o8c130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781302.RAHcpyCqVX-A5GpDeV7l-YPb-CO6m8670lzuO0v9J9o8c130_provenance.
• NP978385.RAPHW1DnKidMtar9ID7XQ3YIL3C2-EtXvo8jTCCkXqkAk130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP978385.RAPHW1DnKidMtar9ID7XQ3YIL3C2-EtXvo8jTCCkXqkAk130_provenance.
• NP781443.RAzSzo_iPyracBcntqmpab8EPWuDxMb4HQPZB27e00DLA130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781443.RAzSzo_iPyracBcntqmpab8EPWuDxMb4HQPZB27e00DLA130_provenance.
• NP496753.RAPmHl1quos4De1larACxnV7D5_NDRq3CRlPbiRulkPGc130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496753.RAPmHl1quos4De1larACxnV7D5_NDRq3CRlPbiRulkPGc130_provenance.
• NP913875.RA-9mN7IZDzbcLDUMqTkuZmhKRHj946O7Vv7BIcSQRKfI130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913875.RA-9mN7IZDzbcLDUMqTkuZmhKRHj946O7Vv7BIcSQRKfI130_provenance.
• NP914037.RAwzIAnhglS_Dq_S86RWqkRMRUIeczekTwAB9K-ofNuME130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914037.RAwzIAnhglS_Dq_S86RWqkRMRUIeczekTwAB9K-ofNuME130_provenance.
• NP873051.RAzivO35St5XAi_xSjhSy8twDkr8y6P6ry0Ejw4WTfcFk130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873051.RAzivO35St5XAi_xSjhSy8twDkr8y6P6ry0Ejw4WTfcFk130_provenance.
• NP496740.RA70__5h0dsxbrmfeuR0Wj39B2nGG_PILy9xUb4vKMnXo130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496740.RA70__5h0dsxbrmfeuR0Wj39B2nGG_PILy9xUb4vKMnXo130_provenance.
• NP496745.RA8s3OsbyxozpUiyUKKGGrpTbTj4Ug4slqunf09zTRTAA130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496745.RA8s3OsbyxozpUiyUKKGGrpTbTj4Ug4slqunf09zTRTAA130_provenance.
• NP496747.RA1EtWJpPUmxbwdSsmJItEYfaigc3woexBGEW6j20rXK4130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496747.RA1EtWJpPUmxbwdSsmJItEYfaigc3woexBGEW6j20rXK4130_provenance.
• NP496750.RA5n0eStJHTh8d_lnfc4qDO4tZlGxHmXFkKCFmE6RFE_4130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496750.RA5n0eStJHTh8d_lnfc4qDO4tZlGxHmXFkKCFmE6RFE_4130_provenance.
• NP496751.RA0UjFP8j84mZzO7oRCEC2SWQfXSUn9kpMIG15oa0bz_Y130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496751.RA0UjFP8j84mZzO7oRCEC2SWQfXSUn9kpMIG15oa0bz_Y130_provenance.
• NP496754.RA1-Aw0gBxI20N5GchdWxzcVx8YUGep4IrZ2LDLBXAd04130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496754.RA1-Aw0gBxI20N5GchdWxzcVx8YUGep4IrZ2LDLBXAd04130_provenance.
• NP496756.RA7kbdK_pqxr6KYYgt58o48Z2yKsDHewkHnWkSI3e7HuU130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496756.RA7kbdK_pqxr6KYYgt58o48Z2yKsDHewkHnWkSI3e7HuU130_provenance.
• NP496757.RA008gwwdPPRVzQt_97BEVNlywP0132u4fkYL6H0LMpg8130_assertion description "[36.6% of the patients with MDS and myelofibrosis developed a transformation into ANLL during the course of the disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496757.RA008gwwdPPRVzQt_97BEVNlywP0132u4fkYL6H0LMpg8130_provenance.